By Nascent Biotech Posted November 9, 2019 In BJCR-104(10) copy2019-11-092019-11-09http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 BJCR-104(10) copy Recent PostsNascent Announces the Completion of Its Phase 1 Clinical TrialsNascent Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNBIO Fits Profile for Strategy Targeting Early Stage BiotechNascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial